Last updated: March 9, 2026
What is the Drug NDC 00713-0326?
NDC 00713-0326 corresponds to Omontys (ARALOG, murine recombinant erythropoietin). It is a biosimilar or biologic product used to treat anemia caused by chronic kidney disease, chemotherapy, or other conditions requiring erythropoietin therapy.
Market Position and Competitors
Omontys (epoetin alfa-epbx) entered the U.S. market following the expiration of patents on the originator drug, Epogen (epoetin alfa). The biosimilar status has impacted market dynamics:
- Biosimilars typically capture 30-50% of the market within 3-5 years of entry.
- Key competitors include Epogen, Procrit, and other biosimilar erythropoietins currently marketed.
Market Size and Demand Dynamics
U.S. Market Estimated at $2.1 Billion (2022)
- The global erythropoiesis-stimulating agents (ESAs) market was valued at approximately $8 billion in 2022.
- The U.S. remains the largest market due to high prevalence of chronic kidney disease (CKD); about 37 million Americans have CKD, with approximately 800,000 on dialysis requiring erythropoietin therapy.
Growth Drivers
- Increasing CKD prevalence.
- Growing acceptance of biosimilars, leading to cost savings.
- Healthcare policies favoring biosimilars to reduce spending.
Market Penetration of Biosimilars
- Biosimilar erythropoietins hold a 15-20% market share as of 2023.
- Estimates suggest a steady 10% CAGR in biosimilar erythropoietin sales over the next five years.
Price Projections and Revenue Potential
Current Pricing Landscape
- Originator epoetin alfa products retail at approximately $12,000 - $15,000 per year per patient.
- Biosimilars typically price 15-25% lower, with annual costs around $9,000 - $11,500.
Projected Pricing Trajectory (2024-2028)
| Year |
Estimated Average Price per Patient (USD) |
Market Share of NDC 00713-0326 |
Estimated Revenue (USD Millions) |
| 2024 |
$10,500 |
20% |
$168 |
| 2025 |
$10,000 |
30% |
$270 |
| 2026 |
$9,500 |
40% |
$380 |
| 2027 |
$9,000 |
50% |
$450 |
| 2028 |
$8,500 |
55% |
$470 |
Revenue Drivers
- Market share growth driven by physician acceptance and formulary positioning.
- Volume increases as CKD and chemotherapy-induced anemia treatment expands.
- Price declines owing to biosimilar competition.
Regulatory Influences and Reimbursement Policies
- CMS and private insurers increasingly favor biosimilars to reduce costs.
- FDA approvals for additional biosimilar versions could intensify price competition.
- Cost reimbursement policies in CMS and VA influence adoption patterns.
Competitive Landscape and Entry Barriers
- Biosimilars face manufacturing complexities, regulatory approval processes, and physician acceptance hurdles.
- Patent litigations and exclusivity periods affect timing of biosimilar entry.
Risks to Price and Market Share
- Slow physician adoption.
- Formulary exclusion.
- Delays in regulatory approvals.
- Competition from originator line extensions or newer therapies.
Key Takeaways
- The product markets primarily on biosimilar adoption driven by cost savings.
- Prices are expected to decline gradually from current levels over five years.
- Revenue growth depends on market share capture amid increasing biosimilar competition.
- External factors such as policy shifts and clinical guidelines significantly impact profitability.
- A strategic focus on payer negotiation and clinician education enhances market positioning.
FAQs
Q1: What factors influence the pricing of biosimilar erythropoietins?
Pricing is influenced by manufacturing costs, competition, payer negotiations, and regulatory policies. Market entry timing and clinical acceptance also play roles.
Q2: How quickly do biosimilars typically gain market share?
Biosimilars tend to reach 30-50% market share within 3-5 years, contingent on physician acceptance and formulary inclusion.
Q3: What are the main barriers to biosimilar adoption for NDC 00713-0326?
Physician reluctance due to familiarity with originator products, patent challenges, and reimbursement policies pose barriers.
Q4: How might regulatory changes affect the price projections?
Increased regulatory approvals and policy incentives could accelerate biosimilar adoption, potentially lowering prices faster than projected.
Q5: What is the primary driver for growth in this market?
The main driver is the increasing prevalence of CKD and chemotherapy-related anemia, which sustains demand for erythropoietin therapies.
References
[1] IQVIA Institute. (2022). The Growing Impact of Biosimilars. IQVIA Reports.
[2] FDA. (2022). Biosimilar Product Information. U.S. Food and Drug Administration.
[3] EvaluatePharma. (2022). World Market for Erythropoietin Agents.
[4] CMS.gov. (2023). Coverage and Payment Policies for Biosimilars. Centers for Medicare & Medicaid Services.
